Search hospitals

>

Connecticut

>

West Haven

CERC (VISN1, West Haven, CT)

Claim this profile

West Haven, Connecticut 06516

Conducts research for Major Depressive Disorder

Conducts research for Hangover

Conducts research for Active Ethanol and Active Iomazenil

Conducts research for Driving Under the Influence (DUI)

Conducts research for Iomazenil Study

5 reported clinical trials

4 medical researchers

Photo of CERC (VISN1, West Haven, CT) in West HavenPhoto of CERC (VISN1, West Haven, CT) in West HavenPhoto of CERC (VISN1, West Haven, CT) in West Haven

Summary

CERC (VISN1, West Haven, CT) is a medical facility located in West Haven, Connecticut. This center is recognized for care of Major Depressive Disorder, Hangover, Active Ethanol and Active Iomazenil, Driving Under the Influence (DUI), Iomazenil Study and other specialties. CERC (VISN1, West Haven, CT) is involved with conducting 5 clinical trials across 11 conditions. There are 4 research doctors associated with this hospital, such as Mohini Ranganathan, MD, Gihyun Yoon, MD, Toral Surti, MD, and Capurso Noah, MD.

Top PIs

Mohini Ranganathan, MD

Connecticut Mental Health Center

4 years of reported clinical research

Studies Substance Abuse
Studies Healthy Subjects
8 reported clinical trials
11 drugs studied

Gihyun Yoon, MD

CERC (VISN1, West Haven, CT)

1 year of reported clinical research

Studies Post-Traumatic Stress Disorder
Studies Alcoholism
4 reported clinical trials
9 drugs studied

Toral Surti, MD

CERC (VISN1, West Haven, CT)

4 years of reported clinical research

Studies Insomnia
1 reported clinical trial
4 drugs studied

Capurso Noah, MD

CERC (VISN1, West Haven, CT)

5 years of reported clinical research

Studies Opiate Dependence
Studies Opioid Use Disorder
1 reported clinical trial
2 drugs studied

Clinical Trials running at CERC (VISN1, West Haven, CT)

Opiate Dependence

Opioid Use Disorder

Image of trial facility.

Buprenorphine Forms

for Opioid Use Disorder

VA-BRAVE will determine whether a 28-day long-acting injectable sub-cutaneous formulation of buprenorphine at a target dose of 300mg is superior in retaining Veterans in opioid treatment and in sustaining opioid abstinence compared to the daily sublingual (under the tongue) buprenorphine formulation at a target dose of 4-32 mg (standard of care). This is an open-label, randomized, controlled trial including 952 Veterans with opioid use disorder (OUD) recruited over 7 years and followed actively for 52 weeks. There are a number of secondary objectives that will be studied as well and include: comorbid substance use, both non-fatal and fatal opioid overdose, HIV and Hepatitis B (HBV) and C (HCV) testing results and risk behaviors, incarceration, quality of life, psychiatric symptoms of depression and posttraumatic stress disorder, housing status, dental health and utilization, and cost-effectiveness.

Recruiting

3 awards

Phase 4

3 criteria

Similar Hospitals nearby

Select from list below to view details

Frequently asked questions

What kind of research happens at CERC (VISN1, West Haven, CT)?

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.